Krazati savings card: $0 a month with commercial insurance

How to pay the least

Ask for the cash price

Krazati

We didn’t find one.

Ask your pharmacy for Krazati’s cash price, and one or two other pharmacies too.
Krazati’s savings card works only with insurance from a job or one you bought.

Free from the maker, if you qualify Bristol Myers Squibb Patient Assistance Foundation (BMSPAF). Or call 1-800-736-0003.

See if you qualify

Compare every option

Brand nameKrazati

Authorized genericadagrasib

Regular genericadagrasib

What you’d pay

Cash priceAsk the pharmacy

Not soldThere isn’t one

Not soldNone found

Same as Krazati?

The original

–

Brand nameThe maker’s card

BMS Access Support Co-Pay Assistance Program

Savings card from Bristol Myers Squibb

No insuranceNeeds insuranceNo cash price listed.

Insurance $0 a month

Or call 1-800-861-0048.

In the maker’s words

“$0 Co-pay per one-month supply…”

From the maker’s offer on bmsaccesssupport.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Maker’s card or discount card?

A discount card like GoodRx lowers the pharmacy’s cash price, but for a brand-name drug that price often stays high. Compare it with the maker’s card above. You can usually use one or the other on a fill, not both.

Authorized genericNot sold

There isn’t one. An authorized generic is Krazati itself, from the same company, sold without the brand name, and usually for less. For now Krazati is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

We didn’t find one. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

KRAZATI is an inhibitor of the RAS GTPase family indicated for:

Non-small cell lung cancer (NSCLC)*

As a single agent, for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC, as determined by an FDA-approved test, who have received at least one prior systemic therapy.

Colorectal cancer (CRC)*

In combination with cetuximab, for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic CRC, as determined by an FDA-approved test, who have received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.
These indications are approved under accelerated approval based on objective response rate (ORR) and duration of response (DOR). Continued approval for these indications may be contingent upon verification and description of a clinical benefit in confirmatory trials.

Source: the FDA label for Krazati (Mirati Therapeutics, Inc), March 25, 2026. Full label on DailyMed

Good to know

“Commercial insurance” means a plan from a job, from the marketplace, or one you buy yourself. A retiree plan that’s part of Medicare counts as Medicare. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.
Most cards need a sign-up on the maker’s site, and many work only if your plan covers the drug. Then give the card’s details to your pharmacy.
Don’t stop or change a medicine without talking to your pharmacist or prescriber.

Prices checked November 2, 2026. Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/krazati/